Global 
Deutschland 
Editorial
Dear colleagues,
In medicine, it is always particularly stimulating when long-established dogmata and treatment algorithms are critically reexamined and revised. Two studies featured in this issue exemplify this.
The BOSS trial by Old et al. challenges established surveillance strategies for Barrett’s esophagus. In this randomized trial, 3453 patients with Barrett’s esophagus were assigned to either 2-yearly surveillance endoscopy or endoscopy performed only when clinically indicated by symptoms. Over a minimum follow-up period of 10 years, no differences were observed in overall survival or cancer-specific survival between both groups. An accompanying health economic analysis further demonstrated that routine endoscopic surveillance, as practiced to date, is not cost-effective. […]
In recent years, several pivotal studies demonstrated the efficacy of immune checkpoint inhibitors in the treatment of gastrointestinal cancer. In colorectal cancer, immunotherapy has shown particularly impressive results in tumors characterized by high microsatellite instability or mismatch repair deficiency (dMMR). The STELLAR-303 trial, a phase 3 trial in patients with advanced colorectal cancer without microsatellite instability-high or dMMR tumors (Hecht et al.), now provides first evidence that an immunotherapy-based regimen with zanzalitinib and atezolizumab allows somewhat better overall survival compared with regorafenib. These results prompt renewed discussion about the potential role of immunotherapy-based approaches for the broader treatment landscape of colorectal cancer in the future.
Beginning with this issue, and alongside our established critical expert opinions, we are introducing a new feature in which 10 selected publications are highlighted as Editors’ Choice as shown below. This designation is intended to help readers more readily to identify articles of particular relevance and interest within each issue. Further developments and new content can be expected in forthcoming editions.
We hope you will find the articles in this issue both informative and inspiring.
Yours sincerely,
Peter Hasselblatt and Tobias Böttler
Department of Internal Medicine II, University Medical Center Freiburg (Germany)
Current literature articles in this edition
Cost-effectiveness of regular surveillance versus endoscopy at need for patients with Barrett’s esophagus: Economic evaluation alongside the Barrett’s Oesophagus Surveillance Study (BOSS) randomized controlled trial
Gastroenterology. 2025;169(6):1244-1252.e7
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment
N Engl J Med. 2025;393(18):1796-1806
Probiotics prescribed with Helicobacter pylori eradication therapy in Europe: Usage pattern, effectiveness, and safety. Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Am J Gastroenterol. 2025;120(11):2644-2659
Helicobacter pylori screening after acute myocardial infarction: The cluster randomized crossover HELP-MI SWEDEHEART trial
JAMA. 2025;334(13):1160-1169
Prophylactic antibiotics for upper gastrointestinal bleeding in patients with cirrhosis: A systematic review and Bayesian meta-analysis
JAMA Intern Med. 2025;185(10):1194-1203
Prevention of rebleeding after primary haemostasis using haemostatic powder in nonvariceal upper gastrointestinal bleeding: A multicentre randomised controlled trial
Gut. 2025;74(11):1821-1827
Whole food diet induces remission in children and young adults with mild to moderate Crohn’s disease and is more tolerable than exclusive enteral nutrition: A randomized controlled trial
Gastroenterology. 2025;169(7):1462-1474.e2
Cutting waste in endoscopy: A multicentre observational study in the German healthcare system
Gut. 2025;74(12):1989-1994
A novel artificial intelligence-based system for quality monitoring during esophagogastroduodenoscopy: A multicenter randomized controlled study
Endoscopy. 2025;57(11):1185-1194